Mathew, Stephen O.2022-05-272022-05-272021-05https://hdl.handle.net/20.500.12503/31152One of the biggest challenges patients with rare diseases face is the availability of safe and effective treatment options. Patients with symptomatic neurogenic orthostatic hypotension have a very limited number of pharmacological treatment options available, none of which are approved by the FDA for long term use. This study reviewed preliminary data from a single site in a nationwide clinical trial testing the long-term effectiveness of Droxidopa in patients with symptomatic neurogenic orthostatic hypotension. Long-term effectiveness was measured using two different patient reported surveys completed at various time points in the study. This data was analyzed using a linear regression as well as other descriptive statistics like mean, median, mode and range to assess the effectiveness of Droxidopa over time.application/pdfendroxidopaneurogenic orthostatic hypotensionHypotension, OrthostaticPatient Reported Outcome MeasuresDroxidopaThesis